June 5, 2025
July 2025 HCPCS Updates – New, Revised, and Discontinued HCPCS Codes and Modifiers
The following information is based on the July 2025 Healthcare Common Procedure Coding System (HCPCS) file. There are several updates that will be effective July 1, 2025. Please keep in mind that the appearance of a HCPCS code is not an indication of coverage by the DME MAC.
This following list contains added HCPCS codes that will be effective July 1, 2025.
HCPCS | DESCRIPTION |
---|---|
J0165 | Injection, epinephrine, not otherwise specified, 0.1 mg |
J0166 | Injection, epinephrine (bpi), not therapeutically equivalent to j0165, 0.1 mg |
J0167 | Injection, epinephrine (hospira), not therapeutically equivalent to j0165, 0.1 mg |
J0168 | Injection, epinephrine (international medication systems), not therapeutically equivalent to j0165, 0.1 mg |
J0169 | Injection, epinephrine (adrenalin), not therapeutically equivalent to j0165, 0.1 mg |
J0618 | Injection, calcium chloride, 2 mg |
J1163 | Injection, diltiazem hydrochloride, 0.5 mg |
J1326 | Injection, zolbetuximab-clzb, 2 mg |
J2312 | Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg |
J2313 | Injection, naloxone hydrochloride (zimhi), 0.01 mg |
J3373 | Injection, vancomycin hydrochloride, 10 mg |
J3374 | Injection, vancomycin hydrochloride (mylan) not therapeutically equivalent to j3373, 10 mg |
J3375 | Injection, vancomycin hydrochloride (xellia), not therapeutically equivalent to j3373, 10 mg |
J3391 | Injection, atidarsagene autotemcel, per treatment |
J7172 | Injection, marstacimab-hncq, 0.5 mg |
J7356 | Injection, foscarbidopa 0.25 mg/foslevodopa 5 mg |
J9174 | Injection, docetaxel (beizray), 1 mg |
J9220 | Injection, indigotindisulfonate sodium, 1 mg |
J9275 | Injection, cosibelimab-ipdl, 2 mg |
J9276 | Injection, zanidatamab-hrii, 2 mg |
J9289 | Injection, nivolumab, 2 mg and hyaluronidase-nvhy |
J9341 | Injection, thiotepa (tepylute), 1 mg |
J9342 | Injection, thiotepa, not otherwise specified, 1 mg |
J9382 | Injection, zenocutuzumab-zbco, 1 mg |
Q2058 | Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion |
The following HCPCS codes have description/verbiage changes that will be effective July 1, 2025.
HCPCS | DESCRIPTION |
---|---|
J1954 | Injection, leuprolide acetate for depot suspension (lutrate depot), 7.5 mg |
J9292 | Injection, pemetrexed dipotassium, 10 mg |
The following list contains discontinued HCPCS codes, along with the cross-walked HCPCS codes (if applicable). Please note, not all discontinued HCPCS codes will have a cross-walked HCPCS code.
HCPCS | DISCONTINUE DATE | CROSSWALK HCPCS CODE |
---|---|---|
J0171 | 06/30/2025 | |
J0173 | 06/30/2025 | |
J2310 | 06/30/2025 | |
J2311 | 06/30/2025 | |
J3370 | 06/30/2025 | |
J3371 | 06/30/2025 | |
J3372 | 06/30/2025 | |
J9340 | 06/30/2025 |